{"protocolSection": {"identificationModule": {"nctId": "NCT01972724", "orgStudyIdInfo": {"id": "PG-9999-301-KR"}, "secondaryIdInfos": [{"id": "U1111-1145-8222", "type": "OTHER", "domain": "World Health Organization"}], "organization": {"fullName": "Takeda", "class": "INDUSTRY"}, "briefTitle": "Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy", "officialTitle": "A 24-Week, Open Label, Phase IV Trial to Evaluate the Efficacy of Pioglitazone 30 mg in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy of Metformin, Sulfonylurea, and Pioglitazone 15 Mg (ADD Trial)", "acronym": "ADD"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-12-16", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2016-10-17", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-10-17", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-10-24", "studyFirstSubmitQcDate": "2013-10-24", "studyFirstPostDateStruct": {"date": "2013-10-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-10-03", "resultsFirstSubmitQcDate": "2017-10-03", "resultsFirstPostDateStruct": {"date": "2018-07-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-08-13", "lastUpdatePostDateStruct": {"date": "2018-09-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Takeda", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the efficacy of pioglitazone 30 mg on glycemic control when used in participants with inadequately controlled type 2 diabetes mellitus treated with stable combinations of metformin and sulfonylurea.", "detailedDescription": "The drug being tested in this study is called pioglitazone. Pioglitazone is being tested to treat glycemic control in adults with inadequately controlled type 2 diabetes mellitus. This study will look at glycemic control in people who take triple oral therapy of metformin, sulfonylurea, and pioglitazone 15 mg.\n\nThe study will enroll approximately 114 patients. All participants will be asked to take one pioglitazone tablet at the same time each day throughout the study as well as continuing their previous dose of metformin and sulfonylurea.\n\nThis multi-center trial will be conducted in Korea. The overall time to participate in this study is up to 25 weeks. Participants will make 4 visits to the hospital or endocrinologist's office, and will be contacted by telephone 7 days after last dose of study drug for a follow-up assessment."}, "conditionsModule": {"conditions": ["Type II Diabetes Mellitus"], "keywords": ["Drug therapy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 114, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Pioglitazone 15 mg (Double-Blind)", "type": "EXPERIMENTAL", "description": "Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.", "interventionNames": ["Drug: Pioglitazone", "Drug: Metformin", "Drug: Sulfonylurea"]}, {"label": "Pioglitazone 30 mg (Double-Blind)", "type": "EXPERIMENTAL", "description": "Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.", "interventionNames": ["Drug: Pioglitazone", "Drug: Metformin", "Drug: Sulfonylurea"]}, {"label": "Pioglitazone 30 mg (Open-Label)", "type": "EXPERIMENTAL", "description": "Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.", "interventionNames": ["Drug: Pioglitazone", "Drug: Metformin", "Drug: Sulfonylurea"]}], "interventions": [{"type": "DRUG", "name": "Pioglitazone", "description": "Pioglitazone tablets", "armGroupLabels": ["Pioglitazone 15 mg (Double-Blind)", "Pioglitazone 30 mg (Double-Blind)", "Pioglitazone 30 mg (Open-Label)"], "otherNames": ["ACTOS"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin as prescribed in clinical practice", "armGroupLabels": ["Pioglitazone 15 mg (Double-Blind)", "Pioglitazone 30 mg (Double-Blind)", "Pioglitazone 30 mg (Open-Label)"]}, {"type": "DRUG", "name": "Sulfonylurea", "description": "Sulfonylurea as prescribed in clinical practice", "armGroupLabels": ["Pioglitazone 15 mg (Double-Blind)", "Pioglitazone 30 mg (Double-Blind)", "Pioglitazone 30 mg (Open-Label)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24", "description": "The change from baseline in glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Week 24. A negative change from baseline indicates improvement.", "timeFrame": "Baseline and Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Fasting Plasma Glucose at Week 24", "description": "The change between the value of fasting serum glucose collected at Week 24 and fasting serum glucose collected at baseline. A negative change from baseline indicates improvement.", "timeFrame": "Baseline and Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria\n\nParticipants meeting the following criteria will be considered for inclusion in the study:\n\n1. Institutional Review Board (IRB)-approved written informed consent form (ICF) must be obtained from the participant or legally authorized representative prior to any trial related procedure (including withdrawal of prohibited medication, if applicable).\n2. Participants with a history of clinical diagnosis of established type 2 diabetes mellitus defined by the American Diabetes Association (ADA) criteria 2012.\n3. Male or female between 18 and 80 years of age.\n4. Participants with stable triple oral therapy of metformin + sulfonylurea + pioglitazone (ACTOS) 15 mg or ACTOSMET(Pioglitazone 15mg/Metformin 850mg) and sulfonylurea for at least 12 weeks at the screening visit.\n5. Participants with glycosylated hemoglobin (HbA1c) \u22657.0% at the screening visit.\n6. Participants with C-peptide \u22651.0 ng/mL at the screening visit.\n7. Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from screening throughout the duration of the study, up to 30 days after the last dose of the study medication.\n\nExclusion Criteria\n\nParticipants meeting any of the following criteria will be excluded from enrollment:\n\n1. Participants with type 1 diabetes mellitus or secondary forms of diabetes.\n2. Participants who have been treated with insulin for \u22657 days within 3 months prior to the screening visit.\n3. Participants with a history of bladder cancer or participants with active bladder cancer.\n4. Participants with a history of acute diabetic complications such as diabetic ketoacidosis.\n5. Participants with a history of acute or chronic metabolic acidosis, including diabetic ketoacidosis.\n6. Participants with unstable or rapidly progressive diabetic retinopathy, nephropathy (estimated glomerular filtration rate \\[eGFR\\] \\<60mL/min/1.73m2).\n7. Participants with cardiac insufficiency (e.g., a myocardial infarction, a coronary angioplasty or bypass graft, unstable angina, transient ischemic attacks, or a documented cerebrovascular accident within 6 months prior to the screening visit).\n8. Participants with cardiac failure or history of cardiac failure (New York Heart Association \\[NYHA\\] Stages 3 to 4).\n9. Participants with a serum alanine transaminase (ALT) level \u22652.5 times the upper limit of normal (ULN), active liver disease, or jaundice.\n10. Participants taking concomitant gemfibrozil or other strong cytochrome P450 (CYP)2C8 inhibitors.\n11. Participants with a history of recurrent or severe hypoglycemia.\n12. Participants with a history of any hemoglobinopathy (such as hemolytic anemias or sickle cell disease) that may affect determination of HbA1c.\n13. Participants with uninvestigated microscopic hematuria\n14. Participants with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, since the study drug contains lactose.\n15. Participants with any other condition judged by the Investigator as unsuitable for the study.\n16. Participants who have used any investigational or experimental drugs or devices within 60 days of the screening visit.\n17. Lactating or pregnant female. A positive pregnancy test before the first administration of investigational medicinal product (IMP) or breastfeeding.\n18. Male participants planning to father during clinical trial conduct or within 3 months after the last planned dose of the IMP.\n19. Participants were previously enrolled into the current clinical trial.\n20. The participants participated in the active treatment phase of another clinical trial where a persisting pharmacodynamic effect of the IMP of that clinical trial cannot be excluded.\n21. Participants are considered unable or unwilling to co-operate adequately, i.e., to follow clinical trial procedures after Investigator has adequately instructed (e.g., language difficulties, etc.) or participants are anticipated not to be available for scheduled clinical trial visits/procedures.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Takeda", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Chagwon", "country": "Korea, Republic of"}, {"city": "Daegu", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"city": "Daejeon", "country": "Korea, Republic of", "geoPoint": {"lat": 36.32139, "lon": 127.41972}}, {"city": "Gwangju", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"city": "Gyeonggi-do", "country": "Korea, Republic of", "geoPoint": {"lat": 37.58944, "lon": 126.76917}}, {"city": "Jeonju", "country": "Korea, Republic of", "geoPoint": {"lat": 35.82194, "lon": 127.14889}}, {"city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"city": "Ulsan", "country": "Korea, Republic of", "geoPoint": {"lat": 35.53722, "lon": 129.31667}}, {"city": "Wonju", "country": "Korea, Republic of", "geoPoint": {"lat": 37.35139, "lon": 127.94528}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants with a diagnosis of Type 2 Diabetes Mellitus were enrolled equally in one of 2 treatment groups in the Double-Blind study: pioglitazone15 mg + metformin + sulfonylurea or pioglitazone pioglitazone 30 mg plus metformin + sulfonylurea. Participants received pioglitazone 30 mg + metformin + sulfonylurea in the Open Label study.", "recruitmentDetails": "Participants took part in the study at 15 investigative sites in Korea from 16 December 2013 to 17 October 2016.", "groups": [{"id": "FG000", "title": "Pioglitazone 15 mg (Double-Blind)", "description": "Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks."}, {"id": "FG001", "title": "Pioglitazone 30 mg (Double-Blind)", "description": "Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks."}, {"id": "FG002", "title": "Pioglitazone 30 mg (Open-Label)", "description": "Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks."}], "periods": [{"title": "Double-Blind", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Intent-to-treat:Received Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Rescue Criteria Met", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal of Consent", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Significant Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Open-Label", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "77"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "72"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Withdrew Consent", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Significant Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "ITT population included participants who took at least one dose of study drug.", "groups": [{"id": "BG000", "title": "Pioglitazone 15 mg (Double-Blind)", "description": "Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks."}, {"id": "BG001", "title": "Pioglitazone 30 mg (Double-Blind)", "description": "Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks."}, {"id": "BG002", "title": "Pioglitazone 30 mg (Open-Label)", "description": "Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "77"}, {"groupId": "BG003", "value": "111"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "59.6", "spread": "8.73", "lowerLimit": "44", "upperLimit": "75"}, {"groupId": "BG001", "value": "57.0", "spread": "12.0", "lowerLimit": "31", "upperLimit": "74"}, {"groupId": "BG002", "value": "59.2", "spread": "7.88", "lowerLimit": "39", "upperLimit": "76"}, {"groupId": "BG003", "value": "58.6", "lowerLimit": "31", "upperLimit": "76"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "35"}, {"groupId": "BG003", "value": "51"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "42"}, {"groupId": "BG003", "value": "60"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "77"}, {"groupId": "BG003", "value": "111"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Asian", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "77"}, {"groupId": "BG003", "value": "111"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Korea, Republic Of", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "77"}, {"groupId": "BG003", "value": "111"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "161.94", "spread": "8.392", "lowerLimit": "147.0", "upperLimit": "175.0"}, {"groupId": "BG001", "value": "163.50", "spread": "9.702", "lowerLimit": "151.0", "upperLimit": "185.0"}, {"groupId": "BG002", "value": "163.25", "spread": "9.148", "lowerLimit": "145.9", "upperLimit": "182.5"}, {"groupId": "BG003", "value": "162.89", "lowerLimit": "145.9", "upperLimit": "185.0"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70.39", "lowerLimit": "48.0", "upperLimit": "97.0"}, {"groupId": "BG001", "value": "71.20", "lowerLimit": "47.5", "upperLimit": "100.0"}, {"groupId": "BG002", "value": "70.38", "lowerLimit": "46.3", "upperLimit": "101.0"}, {"groupId": "BG003", "value": "70.65", "lowerLimit": "46.3", "upperLimit": "101.0"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "26.86", "lowerLimit": "22.2", "upperLimit": "36.7"}, {"groupId": "BG001", "value": "26.46", "lowerLimit": "20.9", "upperLimit": "30.8"}, {"groupId": "BG002", "value": "26.25", "lowerLimit": "19.0", "upperLimit": "34.6"}, {"groupId": "BG003", "value": "26.52", "lowerLimit": "19.0", "upperLimit": "36.7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24", "description": "The change from baseline in glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Week 24. A negative change from baseline indicates improvement.", "populationDescription": "Intent-to-treat population was defined as all participants who took at least 1 dose of the study drug. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of glycosylated hemoglobin", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Pioglitazone 15 mg (Double-Blind)", "description": "Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks."}, {"id": "OG001", "title": "Pioglitazone 30 mg (Double-Blind)", "description": "Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks."}, {"id": "OG002", "title": "Pioglitazone 30 mg (Open-Label)", "description": "Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "76"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.0003", "spread": "0.00725"}, {"groupId": "OG001", "value": "-0.0030", "spread": "0.00894"}, {"groupId": "OG002", "value": "-0.0275", "spread": "0.21126"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose at Week 24", "description": "The change between the value of fasting serum glucose collected at Week 24 and fasting serum glucose collected at baseline. A negative change from baseline indicates improvement.", "populationDescription": "Intent-to-treat population was defined as all participants who took at least 1 dose of the study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Pioglitazone 15 mg (Double-Blind)", "description": "Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks."}, {"id": "OG001", "title": "Pioglitazone 30 mg (Double-Blind)", "description": "Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks."}, {"id": "OG002", "title": "Pioglitazone 30 mg (Open-Label)", "description": "Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "77"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.6727", "spread": "1.80662"}, {"groupId": "OG001", "value": "-0.4278", "spread": "1.88067"}, {"groupId": "OG002", "value": "-0.4412", "spread": "2.30378"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "First dose of study drug up to 30 days after the last dose of study drug (Up to Week 28)", "description": "At each visit investigator had to document any occurrence of adverse events (AEs) and abnormal laboratory findings. Any event spontaneously reported by participant or observed by investigator was recorded, irrespective of relation to study treatment. For other AEs a result of 0 in the table means there are no participants at a threshold of \\>=5%.", "eventGroups": [{"id": "EG000", "title": "Pioglitazone 15 mg (Double-Blind)", "description": "Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.", "seriousNumAffected": 1, "seriousNumAtRisk": 17, "otherNumAffected": 3, "otherNumAtRisk": 17}, {"id": "EG001", "title": "Pioglitazone 30 mg (Double-Blind)", "description": "Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 17, "otherNumAffected": 7, "otherNumAtRisk": 17}, {"id": "EG002", "title": "Pioglitazone 30 mg (Open-Label)", "description": "Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.", "seriousNumAffected": 3, "seriousNumAtRisk": 77, "otherNumAffected": 0, "otherNumAtRisk": 77}], "seriousEvents": [{"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Facial bones fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 77}]}, {"term": "Pneumothorax traumatic", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 77}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 77}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 77}]}, {"term": "Rotator cuff syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 77}]}], "otherEvents": [{"term": "Conjunctival haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Eyelid oedema", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Folliculitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Onychomycosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Tinea pedis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Ligament injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Venom poisoning", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Post herpetic neuralgia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 77}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property."}, "pointOfContact": {"title": "Medical Director", "organization": "Takeda", "email": "trialdisclosures@takeda.com", "phone": "+1-877-825-3327"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type II Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077205", "term": "Pioglitazone"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1693", "name": "Pioglitazone", "asFound": "Registry", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}